Bristol-Myers Squibb Plans To Build Biologics Facility In The U.S.

Hooper to Update Investors on Biologics Plans at Conference Today

NEW YORK, NY (March 8, 2006) - Bristol-Myers Squibb Company (NYSE:BMY) said today that it will build its new biologics facility in the United States. At its regularly scheduled meeting on March 7, the company’s Board of Directors approved a capital expenditure in the amount of $660 million for the construction of a large-scale multi-product bulk biologics manufacturing facility. The facility will be modular in design in order to accommodate future expansion.

Anthony C. Hooper, President, U.S. Pharmaceuticals, will discuss the company’s biologics plans and other recent company developments at the Cowen & Co. 26th Annual Health Care Conference in Boston today. The conference will be webcast at www.bms.com at 1:40 p.m. ET. Mr. Hooper will update investors on the recent launch of ORENCIA® (abatacept), the company’s first internally developed biologic. ORENCIA was approved by the U.S. Food and Drug Administration (FDA) in December 2005 for the treatment of rheumatoid arthritis and has been available to patients since mid-February. Mr. Hooper will also update investors on ERBITUX®, which it co-markets with ImClone Systems Incorporated. On March 1, ERBITUX received FDA approval for use in the treatment of squamous cell carcinoma of the head and neck. He will also discuss the recent approval of EMSAM® (selegiline transdermal system), a transdermal patch that was approved by the FDA on Feb. 27 for the treatment of major depressive disorder in adults.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

Contact Information

Tony Plohoros

Communications

Bristol-Myers Squibb

Contact via E-mail